1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Synovics Pharmaceuticals, Inc.

Synovics Pharmaceuticals, Inc.

SYVC
Synovics Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
-NaN
- -
2,983.00Market Cap
Synovics Pharmaceuticals, Inc.
SYVC
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
TTM
FRC
0.01
0.76
1.7
0.76
0.03
0.01
0.01
0.01
0.01
- -
0.4
1.23
1.1
0.66
Revenue per Share
-1.3
-3.85
-2.47
-1.36
-0.75
-0.64
-0.42
-0.17
-0.14
-0.14
-0.33
-1.09
-0.17
-0.17
Basic EPS, GAAP
-0.94
-3.34
-3.11
-0.81
-0.44
-0.37
-0.17
-0.1
-0.08
-0.12
-0.26
-0.23
0.13
0.06
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.22
-5.44
-7.13
-7.8
-8.43
-8.41
-9.2
-9.37
-5.34
-2.23
-2.05
-3.89
-3.34
-2.93
Book Value per Share
2.28
2.5
1.79
0.66
0.36
-0.04
-0.44
-0.62
-0.08
-0.2
-0.57
-1.14
-0.33
-0.46
Tangible Book Value per Share
2
3
4
4
4
5
4
4
8
20
26
19
24
29
Basic Weighted Avg Shares
- -
2
6
3
- -
- -
- -
- -
- -
- -
11
23
26
19
Sales/Revenue/Turnover
-14,884.4
-519.5
-183.72
-175.98
-2,224.95
-6,609.33
-3,352.64
-1,383.04
-796.23
-23,334.53
-34.41
-43.74
-9.57
-22.62
Operating Margin (%)
- -
- -
1
1
- -
- -
- -
- -
- -
- -
1
- -
1
-2
Depreciation Expense
-3
-12
-9
-6
-3
-3
-2
-1
-1
-3
-9
-21
-4
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-15,037.74
-508.5
-145.52
-179.57
-2,346.27
-7,677.88
-5,028.69
-2,375.14
-1,138.37
-35,537.84
-81.5
-88.88
-15.43
-26.42
Profit Margin (%)
5
1
1
- -
-2
-2
-3
-4
-3
-5
-5
-19
-6
-13
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
12
6
4
2
LT Debt
5
9
8
3
2
1
-1
-1
1
11
13
-8
5
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jan'09
Apr'09
Jul'09
ST Debt
2
3
3
LT Borrowings
3
2
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
1
1
1
Shares Outstanding
30
30
29
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jan'09
Apr'09
Jul'09
Total Current Assets
7
5
5
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
4
3
2
Inventories
3
2
2
Total Current Liabilities
14
15
18
Payables & Accruals
12
12
15
ST Debt
2
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
44.94%
136.29%
-161.72%
Free Cash Flow
7.61%
59.95%
-171.8%
Net Income, GAAP
27.75%
92.79%
-80.79%
Sales/Revenue/Turnover
12,829.12%
25,704.98%
10.62%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
5
6
7
5
23
2008
4
6
8
8
26
2009
7
3
2
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
-0.09
-0.23
-0.25
- -
-1.09
2008
-0.12
-0.14
0.02
- -
-0.17
2009
-0.04
-0.09
-0.07
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
Similar Companies
Mobile Lads Corp. (MOBO)
OSE Immunotherapeutics S.A. (OSE.PA)
Ever Supreme Bio Technology Co., Ltd (6712.TWO)
Lakefront Biotherapeutics (GLPG.AS)
Immuron Limited (IMRN)
Northwest Biotherapeutics, Inc. (NWBO)
Business
Synovics Pharmaceuticals, Inc. (SYVC) develops, manufactures, commercializes, packages, and distributes generic over-the-counter (OTC) pharmaceutical products and generic prescription drug products primarily in the United States; its OTC categories encompass analgesics, cough and cold remedies, antihistamines, asthma relief treatments, laxatives, and antacids. The company operates through subsidiaries Kirk Pharmaceuticals, LLC, which manufactures and distributes OTC products, and ANDAPharm, LLC, which focuses on product research, active compound development, and prescription manufacturing. Founded in 1983 and headquartered in Fort Lauderdale, Florida, Synovics targets chain drug stores, wholesalers, and distributors with its private-label and store-brand offerings. In a major historical development, the company completed a $21.25 million financing in 2006 to acquire Kirk Pharmaceuticals, LLC, and established a strategic relationship with Maneesh Pharmaceuticals for R&D, manufacturing, and marketing synergies, including potential distribution in Europe, Asia, and Latin America; it also pursued first-to-file ANDAs and 505(b)(2) New Drug Applications for controlled-release drugs. Formerly known as Bionutrics Inc., Synovics changed its name in 2006 amid these expansions, though no significant partnerships, funding rounds, acquisitions, or product launches have been publicly reported in the last 1-2 years.